Aliases & Classifications for Cardiac Arrhythmia

MalaCards integrated aliases for Cardiac Arrhythmia:

Name: Cardiac Arrhythmia 56 29 6 17
Adverse Event Associated with Cardiac Arrhythmia 71
Premature Cardiac Complex 71
Extrasystoles 56

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
cardiac arrhythmia:
Clinical modifier sudden death
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 56 115000
ICD10 32 I49.8 I49.9
MedGen 41 C0003811
SNOMED-CT via HPO 68 263681008 26636000 88425004
UMLS 71 C0340464 C1560249

Summaries for Cardiac Arrhythmia

MalaCards based summary : Cardiac Arrhythmia, also known as adverse event associated with cardiac arrhythmia, is related to cardiac conduction defect and familial short qt syndrome, and has symptoms including pulsus trigeminus and bigeminal pulse. An important gene associated with Cardiac Arrhythmia is SCN5A (Sodium Voltage-Gated Channel Alpha Subunit 5), and among its related pathways/superpathways are Transmission across Chemical Synapses and Cardiac conduction. The drugs Diphenhydramine and Histamine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and lung, and related phenotypes are abnormality of the nervous system and polymorphic and polytopic ventricular extrasystoles

More information from OMIM: 115000

Related Diseases for Cardiac Arrhythmia

Diseases related to Cardiac Arrhythmia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 558)
# Related Disease Score Top Affiliating Genes
1 cardiac conduction defect 32.4 SCN5A RYR2 KCNQ1 KCNH2
2 familial short qt syndrome 31.6 KCNQ1 KCNJ2 KCNH2
3 arrhythmogenic right ventricular dysplasia, familial, 8 31.3 RYR2 PKP2 JUP
4 ventricular fibrillation, paroxysmal familial, 1 31.2 SCN5A RYR2 KCNQ1 KCNH2 KCNE2 KCNE1
5 progressive familial heart block, type ia 31.2 SCN5A ANK2
6 brugada syndrome 5 31.1 TANGO2 SCN5A
7 sick sinus syndrome 31.0 SCN5A RANGRF KCNJ2 CACNA1C ANK2
8 syncope 30.7 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2
9 long qt syndrome 6 30.5 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1
10 brugada syndrome 3 30.4 KCNE2 CACNA1C-AS1 CACNA1C ANK2
11 brugada syndrome 4 30.4 SCN5A KCNQ1 KCNJ2 KCNH2 CACNA1C
12 sudden infant death syndrome 30.4 SCN5A RYR2 KCNQ1 KCNH2
13 brugada syndrome 1 30.2 SCN5A RYR2 KCNH2 AKAP9
14 atrial fibrillation 30.2 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
15 third-degree atrioventricular block 30.2 SCN5A KCNJ2
16 congestive heart failure 30.0 SCN5A RYR2 KCNQ1 KCNJ2 KCNE2 CACNA1C
17 long qt syndrome 12 29.9 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1 ANK2
18 atrial standstill 1 29.9 SCN5A RYR2 PKP2 JUP
19 left bundle branch hemiblock 29.9 SCN5A RYR2 PKP2 JUP
20 long qt syndrome 9 29.8 SCN5A KCNQ1 KCNJ2 KCNE2 KCNE1 CACNA1C
21 wolff-parkinson-white syndrome 29.8 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1
22 right bundle branch block 29.8 SCN5A RANGRF PKP2 KCNH2 CACNA1C
23 hyperkalemic periodic paralysis 29.7 SCN5A KCNJ2
24 atrioventricular block 29.7 SCN5A RYR2 KCNQ1 KCNH2 KCNE2 KCNE1
25 cardiac arrest 29.7 SCN5A RYR2 KCNQ1 KCNH2 ANK2 AKAP9
26 long qt syndrome 11 29.6 KCNQ1 KCNJ2 KCNE2 KCNE1 CACNA1C ANK2
27 long qt syndrome 13 29.5 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1
28 familial long qt syndrome 29.3 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1
29 long qt syndrome 3 29.3 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
30 long qt syndrome 2 29.3 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
31 hypokalemic periodic paralysis, type 1 29.2 SCN5A KCNJ2 KCNE1 CACNA1C
32 andersen cardiodysrhythmic periodic paralysis 29.2 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
33 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 28.8 SCN5A RYR2 PKP2 KCNQ1 KCNJ2 KCNH2
34 long qt syndrome 5 28.7 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
35 sinoatrial node disease 28.7 SCN5A RYR2 RANGRF KCNQ1 KCNJ2 KCNH2
36 leopard syndrome 28.7 PKP2 KCNQ1 KCNH2 JUP CACNA1C
37 long qt syndrome 1 28.4 SCN5A RYR2 RANGRF PKP2 KCNQ1 KCNJ2
38 heart disease 28.2 SCN5A RYR2 PKP2 KCNQ1 KCNJ2 KCNH2
39 jervell and lange-nielsen syndrome 1 28.0 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1
40 short qt syndrome 27.8 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
41 arrhythmogenic right ventricular cardiomyopathy 27.4 SCN5A RYR2 PKP2 KCNH2 KCNE1 JUP
42 long qt syndrome 27.1 SCN5A RYR2 PKP2 KCNQ1 KCNJ2 KCNH2
43 brugada syndrome 26.8 SCN5A RYR2 RANGRF PKP2 KCNQ1 KCNJ2
44 catecholaminergic polymorphic ventricular tachycardia 26.6 SCN5A RYR2 PKP2 KCNQ1 KCNJ2 KCNH2
45 dilated cardiomyopathy 26.6 SCN5A RYR2 PKP2 KCNQ1 KCNJ2 KCNH2
46 timothy syndrome 26.5 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
47 familial atrial fibrillation 26.1 SCN5A RYR2 RANGRF PKP2 KCNQ1 KCNJ2
48 metabolic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 12.8
49 intellectual developmental disorder with cardiac arrhythmia 12.8
50 language delay and attention deficit-hyperactivity disorder/cognitive impairment with or without cardiac arrhythmia 12.7

Comorbidity relations with Cardiac Arrhythmia via Phenotypic Disease Network (PDN):


Familial Atrial Fibrillation First-Degree Atrioventricular Block
Heart Disease Hypertension, Essential
Intermediate Coronary Syndrome Mitral Valve Disease
Sinoatrial Node Disease

Graphical network of the top 20 diseases related to Cardiac Arrhythmia:



Diseases related to Cardiac Arrhythmia

Symptoms & Phenotypes for Cardiac Arrhythmia

Human phenotypes related to Cardiac Arrhythmia:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 31 HP:0000707
2 polymorphic and polytopic ventricular extrasystoles 31 HP:0006696

Symptoms via clinical synopsis from OMIM:

56
Cardiac:
arrhythmia
polymorphic and polytopic ventricular extrasystoles

Neuro:
syncopal attacks

Misc:
sudden death

Clinical features from OMIM:

115000

UMLS symptoms related to Cardiac Arrhythmia:


pulsus trigeminus, bigeminal pulse

MGI Mouse Phenotypes related to Cardiac Arrhythmia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.61 CACNA1C GNB5 JUP KCNH2 KCNJ2 KCNQ1
2 muscle MP:0005369 9.28 CACNA1C GNB5 JUP KCNH2 KCNJ2 KCNQ1

Drugs & Therapeutics for Cardiac Arrhythmia

Drugs for Cardiac Arrhythmia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 301)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
2
Histamine Approved, Investigational Phase 4 51-45-6 774
3
Promethazine Approved, Investigational Phase 4 60-87-7 4927
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
6
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
7
Racepinephrine Approved Phase 4 329-65-7 838
8
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
9
leucovorin Approved Phase 4 58-05-9 6006 143
10
Ibutilide Approved Phase 4 122647-31-8, 122647-32-9 60753
11
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
12
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
14
Methadone Approved Phase 4 76-99-3 4095
15
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
16
Morphine Approved, Investigational Phase 4 57-27-2 5288826
17
Adenosine Approved, Investigational Phase 4 58-61-7 60961
18
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
19
Bisoprolol Approved Phase 4 66722-44-9 2405
20
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
21
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
22
Metformin Approved Phase 4 657-24-9 14219 4091
23
Insulin glargine Approved Phase 4 160337-95-1
24
Glucagon Approved Phase 4 16941-32-5
25
Insulin lispro Approved Phase 4 133107-64-9
26
Insulin aspart Approved Phase 4 116094-23-6 16132418
27
Zinc Approved, Investigational Phase 4 7440-66-6 32051
28
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
29
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
30
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
31
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
32
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
33
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
34
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
35
nivolumab Approved Phase 4 946414-94-4
36
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
37
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
38
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
39
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
40 Tocotrienol Investigational Phase 4 6829-55-6
41 Antiemetics Phase 4
42 Dermatologic Agents Phase 4
43 Antipruritics Phase 4
44 Histamine H1 Antagonists Phase 4
45 Histamine Antagonists Phase 4
46
Histamine Phosphate Phase 4 51-74-1 65513
47 Anti-Allergic Agents Phase 4
48 Antipsychotic Agents Phase 4
49 Dopamine Agents Phase 4
50 Dopamine D2 Receptor Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 310)
# Name Status NCT ID Phase Drugs
1 Use of Diphenhydramine as an Adjunctive Sedative for Colonoscopy in Patients Chronically on Opioids Unknown status NCT01967433 Phase 4 Diphenhydramine;Placebo
2 Changes of Heart Rate Variability in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4 Aripiprazole; Quetiapine
3 Early Loop-Recorder in Suspected Arrhythmogenic Syncope Completed NCT00170261 Phase 4
4 Study on the Role of a Combination of Nutraceuticals (Ritmonutra) With an Effect on Benign Supraventricular and Ventricular Arrhythmias in Subjects Free of a Specific Organic Heart Disease. Completed NCT01647984 Phase 4
5 Hemodynamic and Electrocardiographic Effects of Hyaluronidase Associated With Local Anaesthetics: a Double-blind "Split-mouth" Controlled Trial. Completed NCT01719978 Phase 4 3.6mL 2% Mepivacaine with 1:100,000 epinephrine;Hyaluronidase;Placebo
6 Development and Evaluation of a Methadone Protocol for Severe Chronic Pain Management Completed NCT02335398 Phase 4 Methadone
7 CRYptogenic STroke And underLying AF Trial Completed NCT00924638 Phase 4
8 Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation Completed NCT01447862 Phase 4 Brinavess (Vernakalant);Corvert (Ibutilide)
9 Efficacy of Terlipressin Therapy in Acute Variceal Haemorrhage After Endoscopic Variceal Ligation: A Randomised Controlled Clinical Trial Completed NCT03584087 Phase 4 Normal Saline;Terlipressin
10 Supportive Measures in Treatment of Aluminum Phosphide Poisoning as a Trial to Reduce Mortality at Assiut University Hospital Completed NCT03879356 Phase 4 N-acetyl cysteine
11 Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia: Data Collection of Clinical Scar-related VT Cases Completed NCT00851279 Phase 4
12 Pilot Randomized Clinical Trial Comparing the Efficacy of Two Different Hypothermia Temperatures for Treatment of Comatose Patients Recovered From an Out-of-hospital Cardiac Arrest Completed NCT01155622 Phase 4
13 Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter Completed NCT01448265 Phase 4
14 Evaluation of Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
15 Weaning Process in Elderly Intubated Patients Submitted to Inspiratory Muscle Training Completed NCT00922493 Phase 4
16 The Effects of Lidocaine and Magnesium Sulphate on the Attenuation of the Hemodynamic Response to Tracheal Intubation: Single Center, Prospective, Double-Blind and Randomized Study Completed NCT02359370 Phase 4 Lidocaine;Magnesium Sulphate
17 Cavotricuspid Isthmusblock and Circumferential Pulmonary Vein Isolation in Patients With Atrial Fibrillation Completed NCT00247780 Phase 4
18 ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial Completed NCT01058980 Phase 4
19 Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery Completed NCT03800264 Phase 4 Bisoprolol
20 Atrial Fibrillation and Congestive Heart Failure (AF-CHF)Trial Completed NCT00597077 Phase 4
21 FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR Completed NCT01524705 Phase 4 "GLIPULIN:" [insulin glargine, metformin, exenatide (GLP-1-agonist)];Insulin glargine, metformin, prandial insulin
22 Language-based Learning Skills and ADHD: Impact of Treatment With Sustained-release Guanfacine Completed NCT01146002 Phase 4 Guanfacine (sustained release)
23 A Comparison of Isolating the Pulmonary Veins With the Cryoballoon Catheter Versus Radiofrequency Segmental Isolation:a Randomized Controlled Prospective Non-inferiority Trial Completed NCT00774566 Phase 4
24 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
25 Comparison of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure: the SWISS-APERO Randomized Clinical Trial Recruiting NCT03399851 Phase 4
26 Interaction Between Intravenous Magnesium Sulphate and Neostigmine or Sugammadex for the Reversal of a Rocuronium-induced Neuromuscular Block - A Randomized, Double Blinded, Electrophysiological Study Recruiting NCT03497923 Phase 4 Magnesium Sulfate
27 Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study) Recruiting NCT02426944 Phase 4 NOAC
28 Effectiveness of Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Aortic and Mitral Valvular Atrial Fibrillation Patients Active, not recruiting NCT02982850 Phase 4 Dabigatran;Acetylsalicylic acid;Warfarin
29 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting Programmed Cell Death 1 (PD-1) Not yet recruiting NCT03313544 Phase 4 Nivolumab
30 A Multicenter, Randomized, Double-Blind, Controlled Study of EXPAREL for Postsurgical Pain Management in Subjects Undergoing Open Lumbar Spinal Fusion Surgery Terminated NCT03015961 Phase 4 Bupivacaine HCl;EXPAREL and bupivacaine HCl
31 Dabigatran-related Effect on Progression of Atrial Fibrosis in Patients With Atrial Fibrillation Terminated NCT01546883 Phase 4 Dabigatran etexilate (Pradaxa)
32 Cardiovascular Safety Evaluation in Patients With Coronary Artery Disease During Physical Effort After Use Lodenafil Carbonate Withdrawn NCT00817830 Phase 4 lodenafil carbonate
33 Uninterrupted Versus Interrupted Anticoagulation in Atrial Fibrillation Ablation - Cerebral Thromboemboli and Neurocognitive Performance Withdrawn NCT02120560 Phase 4
34 Effect of Electroacupuncture in Diabetic Patients With Gastroparesis Unknown status NCT00227383 Phase 3
35 Phase 3, Prospective, Randomized, Double-blinded, Placebo-controlled Study to Evaluate Efficacy of add-on Therapy With Spironolactone to Reduce Diffuse Myocardial Fibrosis Thus Preventing Recurrent Episodes of Atrial Fibrillation in Patients With Paroxysmal or Persistent Atrial Fibrillation and Preserved Ejection Fraction Compared to Usual Care. Unknown status NCT02764619 Phase 3 Spironolactone;Placebo
36 Influence of a Specific Micronutrient Combination on Symptom Awareness and Heart Rhythm in Patients With Cardiac Arrhythmia Completed NCT02652338 Phase 3
37 Low Versus High Dose Magnesium Sulfate in the Early Management of Rapid Atrial Fibrillation : Randomised Controlled Double Blind Study (LOMAGHI Study) Completed NCT00965874 Phase 3 Magnesium Sulfate high dose;Magnesium Sulfate low dose;Placebos
38 Cardiac Arrhythmia Suppression Trial (CAST) Completed NCT00000526 Phase 3 encainide;flecainide;moricizine
39 Study on Omega-3 Fatty Acids and Ventricular Arrhythmia, a Parallel, Placebo-Controlled, Double Blind Intervention Study Completed NCT00110838 Phase 3
40 Beta-Blocker Evaluation in Survival Trial (BEST) Completed NCT00000560 Phase 3 adrenergic beta antagonists
41 Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE) Completed NCT00000558 Phase 3 angiotensin-converting enzyme inhibitors
42 A Prospective, Randomized, Double-blind Placebo-controlled Study to Determine the Efficacy of 8 mg/Day Oral Perindopril to Prevent the Recurrence of Atrial Fibrillation in Patients With Essential Hypertension Completed NCT00461903 Phase 3 Perindopril
43 Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation Completed NCT02132767 Phase 3 Amiodarone;Rate Control
44 CSP #399 - The Effects of Antiarrhythmic Therapy in Maintaining Stability of Sinus Rhythm in Atrial Fibrillation Completed NCT00007605 Phase 3 Amiodarone;Sotalol
45 Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) Completed NCT00000464 Phase 3 amiodarone;imipramine;mexiletine;procainamide;propafenone;quinidine;sotalol
46 Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Completed NCT00000556 Phase 3 amiodarone;sotalol;propafenone;flecainide;quinidine;moricizine;disopyramide;procainamide;adrenergic beta antagonists;verapamil;diltiazem;digoxin
47 Antiarrhythmics Versus Implantable Defibrillators (AVID) Completed NCT00000531 Phase 3 amiodarone amiodarone;sotalol
48 Comparing Intranasal Dexmedetomidine With Oral Midazolam as Premedication for Older Children Undergoing General Anesthesia for Dental Rehabilitation Completed NCT02250703 Phase 3 Midazolam;Dexmedetomidine
49 A Randomized Double-blind Placebo Force-titration Controlled Study With Bisoprolol in Patients With Chronic Heart Failure Secondary to Chagas´ Cardiomyopathy. Completed NCT00323973 Phase 3 Bisoprolol
50 Diagnosis of Ventilator- Associated Pneumonia in Children: A Comparative Study of Bronchoscopic and Non-Bronchoscopic Methods Completed NCT00495963 Phase 3

Search NIH Clinical Center for Cardiac Arrhythmia

Genetic Tests for Cardiac Arrhythmia

Genetic tests related to Cardiac Arrhythmia:

# Genetic test Affiliating Genes
1 Cardiac Arrhythmia 29

Anatomical Context for Cardiac Arrhythmia

MalaCards organs/tissues related to Cardiac Arrhythmia:

40
Heart, Testes, Lung, Kidney, Liver, Brain, Thyroid

Publications for Cardiac Arrhythmia

Articles related to Cardiac Arrhythmia:

(show top 50) (show all 5443)
# Title Authors PMID Year
1
KCNQ1 and KCNH2 mutations associated with long QT syndrome in a Chinese population. 6
12442276 2002
2
Familial paroxysmal ventricular tachycardia in two sisters. 56
4129426 1974
3
Fatal familial cardiac arrhythmias. Histologic observations on the cardiac conduction system. 56
5016833 1972
4
FAMILIAL POLYTOPIC AND POLYMORPHIC EXTRASYSTOLES. 56
14115011 1964
5
Machine Intelligence in Cardiovascular Medicine. 61
32022759 2020
6
Feasibility of Atrial Fibrillation Screening With Mobile Health Technologies at Pharmacies. 61
31578088 2020
7
Ascleposide, a natural cardenolide, induces anticancer signaling in human castration-resistant prostatic cancer through Na+ /K+ -ATPase internalization and tubulin acetylation. 61
31905252 2020
8
Initial experiences with a novel biodegradable device for percutaneous closure of atrial septal defects: From preclinical study to first-in-human experience. 61
31714687 2020
9
Weighted gene co‑expression network analysis to identify key modules and hub genes associated with atrial fibrillation. 61
31894294 2020
10
The IKs Ion Channel Activator Mefenamic Acid Requires KCNE1 and Modulates Channel Gating in a Subunit-Dependent Manner. 61
31722973 2020
11
Risk Stratification of Older Adults Who Present to the Emergency Department With Syncope: The FAINT Score. 61
31668571 2020
12
Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer. 61
31923729 2020
13
Atrial Fibrillation Prediction With Residual Network Using Sensitivity and Orthogonality Constraints. 61
31825883 2020
14
Is second hand smoking associated with atrial fibrillation risk among women in Israel? A case-control study. 61
32029307 2020
15
Non-vitamin K antagonist oral anticoagulation agents in patients with atrial fibrillation: Insights from Italian monitoring registries. 61
32021902 2020
16
Associations of antiretroviral therapy and comorbidities with neurocognitive outcomes in HIV-1 infected patients. 61
32028325 2020
17
Inflammatory cell infiltration in left atrial appendageal tissues of patients with atrial fibrillation and sinus rhythm. 61
32015492 2020
18
[Present and future relevance of telemedicine in cardiac arrhythmia emergencies]. 61
32020271 2020
19
Effects of white-coat, masked and sustained hypertension on coronary artery stenosis and cardiac arrhythmia. 61
31624353 2020
20
Long-term cardiac arrhythmia and chronotropic evaluation in patients with severe anorexia nervosa (LACE-AN): A pilot study. 61
31917489 2020
21
A self-doping conductive polymer hydrogel that can restore electrical impulse propagation at myocardial infarct to prevent cardiac arrhythmia and preserve ventricular function. 61
31841751 2020
22
Anaphylaxis-induced atrial fibrillation and anesthesia: Pathophysiologic and therapeutic considerations. 61
31929239 2020
23
Video-assisted mediastinoscopy is safe in patients taking antiplatelet or anticoagulant therapy. 61
30178769 2020
24
Effect of habitual cigarette smoking on the index of cardiac electrophysiological balance in apparently healthy individuals. 61
31958651 2020
25
Assessment of a Machine Learning Model Applied to Harmonized Electronic Health Record Data for the Prediction of Incident Atrial Fibrillation. 61
31951272 2020
26
Hip Fracture in Nonagenarians: Characteristics and Factors Related to 30-Day Mortality in 1177 Patients. 61
31992530 2020
27
Psychostimulants/Atomoxetine and Serious Cardiovascular Events in Children with ADHD or Autism Spectrum Disorder. 61
31768949 2020
28
The feasibility and safety of sharp recanalization for superior vena cava occlusion in hemodialysis patients: A retrospective cohort study. 61
31808994 2020
29
Tp-e interval, Tp-e/QT and Tp-e/QTc ratio in hypertensive patients with primary aldosteronism. 61
31204516 2020
30
Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation. 61
31933471 2020
31
Clinical and biochemical outcomes of patients with medium-chain acyl-CoA dehydrogenase deficiency. 61
31836396 2020
32
Impact of extreme temperatures on ambulance dispatches in London, UK. 61
31918315 2020
33
Association of Race and Ethnicity with Vascular Access Type Selection and Outcomes. 61
31476426 2020
34
Cardiac arrhythmia services in Africa from 2011 to 2018: the second report from the Pan African Society of Cardiology working group on cardiac arrhythmias and pacing. 61
31989158 2020
35
Emerging biomarkers for cardiac arrhythmias. 61
31786205 2020
36
The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine. 61
31903798 2020
37
Acute Care Nurses' Arrhythmia Knowledge: Defining Competency. 61
31895469 2020
38
Hyperkalemia in chronic kidney disease. 61
31939533 2020
39
Arrhythmogenic risks of stem cell replacement therapy for cardiovascular diseases. 61
31994198 2020
40
Loss-of-Function Variants in Cytoskeletal Genes Are Associated with Early-Onset Atrial Fibrillation. 61
32013268 2020
41
Identification of patients with atrial fibrillation, a big data exploratory analysis of the UK Biobank. 61
31978903 2020
42
Analysis of Relevant Features from Photoplethysmographic Signals for Atrial Fibrillation Classification. 61
31941071 2020
43
Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. 61
31955707 2020
44
A scoping review and mapping exercise comparing the content of patient-reported outcome measures (PROMs) across heart disease-specific scales. 61
31974688 2020
45
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis. 61
31984481 2020
46
Ankyrin-B p.S646F undergoes increased proteasome degradation and reduces cell viability in the H9c2 rat ventricular cardiomyoblast cell line. 61
31965814 2020
47
A Novel Loss-of-Function Variant in the Chloride Ion Channel Gene Clcn2 Associates with Atrial Fibrillation. 61
31996765 2020
48
Restarting Oral Anticoagulation in Patients with Atrial Fibrillation After an Intracranial Hemorrhage. 61
31985523 2020
49
The use of intracardiac echocardiography catheters in endocardial ablation of cardiac arrhythmia: Meta-analysis of efficiency, effectiveness, and safety outcomes. 61
31976603 2020
50
Fluoroless catheter ablation of cardiac arrhythmia: Is it ready for prime time? 61
31710125 2020

Variations for Cardiac Arrhythmia

ClinVar genetic disease variations for Cardiac Arrhythmia:

6 (show top 50) (show all 100) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KCNH2 NM_172057.2(KCNH2):c.2059dup (p.Leu687fs)duplication Pathogenic 200695 rs794728465 7:150644488-150644489 7:150947400-150947401
2 KCNH2 NM_172057.2(KCNH2):c.1946-2_1947dupduplication Pathogenic 200691 rs794728464 7:150644600-150644601 7:150947512-150947513
3 KCNH2 NM_172057.2(KCNH2):c.1763_1769del (p.Gly588fs)deletion Pathogenic 200676 rs794728457 7:150644870-150644876 7:150947782-150947788
4 KCNH2 NM_172057.2(KCNH2):c.1757del (p.Pro586fs)deletion Pathogenic 200674 rs794728456 7:150644882-150644882 7:150947794-150947794
5 KCNH2 NM_172056.2(KCNH2):c.2053del (p.Arg685fs)deletion Pathogenic 200791 rs794728500 7:150648101-150648101 7:150951013-150951013
6 KCNH2 NM_172056.2(KCNH2):c.1815del (p.Ser606fs)deletion Pathogenic 200789 rs794728499 7:150648666-150648666 7:150951578-150951578
7 KCNH2 NM_172056.2(KCNH2):c.1201_1204dup (p.His402fs)duplication Pathogenic 200630 rs794728434 7:150649865-150649866 7:150952777-150952778
8 KCNH2 NM_172056.2(KCNH2):c.1142del (p.Gly381fs)deletion Pathogenic 200785 rs794728497 7:150649928-150649928 7:150952840-150952840
9 KCNH2 NM_172056.2(KCNH2):c.853_859del (p.Ala285fs)deletion Pathogenic 200618 rs794728428 7:150655204-150655210 7:150958116-150958122
10 KCNH2 NM_172056.2(KCNH2):c.809_812delinsAAAAGC (p.Thr270fs)indel Pathogenic 200614 rs794728426 7:150655251-150655254 7:150958163-150958166
11 KCNH2 NM_172056.2(KCNH2):c.735_754dup (p.Arg252fs)duplication Pathogenic 200612 rs794728425 7:150655308-150655309 7:150958220-150958221
12 KCNH2 NM_172057.2(KCNH2):c.2116del (p.Gln706fs)deletion Pathogenic 200709 rs794728472 7:150644432-150644432 7:150947344-150947344
13 KCNH2 NM_172057.2(KCNH2):c.2085_2092dup (p.Val698fs)duplication Pathogenic 200705 rs794728470 7:150644455-150644456 7:150947367-150947368
14 KCNH2 NM_172057.2(KCNH2):c.2076_2079dup (p.Pro694fs)duplication Pathogenic 200699 rs794728467 7:150644468-150644469 7:150947380-150947381
15 KCNH2 NM_172056.2(KCNH2):c.373_374insGTGG (p.Phe125fs)insertion Pathogenic 200759 rs794728489 7:150656758-150656759 7:150959670-150959671
16 KCNH2 NM_172056.2(KCNH2):c.244_252dup (p.Ile82_Gln84dup)duplication Pathogenic 200717 rs794728476 7:150671853-150671854 7:150974765-150974766
17 KCNH2 NM_172056.2(KCNH2):c.154del (p.Cys52fs)deletion Pathogenic 200809 rs794728508 7:150671952-150671952 7:150974864-150974864
18 KCNH2 NM_172056.2(KCNH2):c.106del (p.Val36fs)deletion Pathogenic 200807 rs794728507 7:150672000-150672000 7:150974912-150974912
19 KCNH2 NM_172056.2(KCNH2):c.100del (p.Ala34fs)deletion Pathogenic 200805 rs794728506 7:150672006-150672006 7:150974918-150974918
20 PKP2 NM_004572.3(PKP2):c.2013del (p.Lys672fs)deletion Pathogenic 202022 rs764817683 12:32974422-32974422 12:32821488-32821488
21 TANGO2 NM_152906.7(TANGO2):c.460G>A (p.Gly154Arg)SNV Pathogenic 208823 rs752298579 22:20049061-20049061 22:20061538-20061538
22 TANGO2 NM_152906.5(TANGO2):c.57-1743_*10769deldeletion Pathogenic 224770 22:20029135-20062954 22:20041612-20075431
23 TANGO2 NM_152906.5(TANGO2):c.146-3605_451+2245deldeletion Pathogenic 224772 22:20048857-20058261
24 PKP2 NM_004572.3(PKP2):c.235C>T (p.Arg79Ter)SNV Pathogenic 6754 rs121434420 12:33031955-33031955 12:32879021-32879021
25 KCNQ1 NM_000218.2(KCNQ1):c.165_187del (p.Gly57fs)deletion Pathogenic 200889 rs794728563 11:2466490-2466512 11:2445260-2445282
26 PKP2 NM_004572.3(PKP2):c.1211dup (p.Val406fs)duplication Pathogenic 45015 rs397516989 12:33003866-33003867 12:32850932-32850933
27 KCNQ1 NM_181798.1(KCNQ1):c.1461_1463del (p.His487del)deletion Pathogenic 53020 rs397508101 11:2869042-2869044 11:2847812-2847814
28 KCNQ1 NM_181798.1(KCNQ1):c.962del (p.Pro321fs)deletion Pathogenic 52977 rs397508087 11:2610029-2610029 11:2588799-2588799
29 PKP2 NM_004572.3(PKP2):c.14del (p.Gly5fs)deletion Pathogenic/Likely pathogenic 45027 rs397516996 12:33049652-33049652 12:32896718-32896718
30 SCN5A NM_198056.2(SCN5A):c.4719C>T (p.Gly1573=)SNV Pathogenic/Likely pathogenic 263423 rs754221948 3:38595864-38595864 3:38554373-38554373
31 TANGO2 NM_152906.7(TANGO2):c.605+1G>ASNV Pathogenic/Likely pathogenic 208824 rs372949028 22:20049207-20049207 22:20061684-20061684
32 KCNE2 NM_172201.1(KCNE2):c.161T>C (p.Met54Thr)SNV risk factor 6053 rs74315447 21:35742938-35742938 21:34370639-34370639
33 SCN5A NM_198056.2(SCN5A):c.3308C>A (p.Ser1103Tyr)SNV risk factor 9393 rs7626962 3:38620907-38620907 3:38579416-38579416
34 RYR2 NM_001035.3(RYR2):c.4040T>G (p.Met1347Arg)SNV Likely pathogenic 36742 rs193922625 1:237754172-237754172 1:237590872-237590872
35 RYR2 NM_001035.3(RYR2):c.14314G>A (p.Gly4772Ser)SNV Likely pathogenic 36734 rs193922622 1:237972216-237972216 1:237808916-237808916
36 RYR2 NM_001035.3(RYR2):c.3251G>A (p.Arg1084Lys)SNV Conflicting interpretations of pathogenicity 36740 rs193922624 1:237729903-237729903 1:237566603-237566603
37 SCN1B NM_199037.3(SCN1B):c.751G>A (p.Val251Ile)SNV Conflicting interpretations of pathogenicity 36757 rs193922728 19:35524946-35524946 19:35034042-35034042
38 RYR2 NM_001035.3(RYR2):c.5586C>T (p.Asp1862=)SNV Conflicting interpretations of pathogenicity 36745 rs193922628 1:237778014-237778014 1:237614714-237614714
39 SCN5A NM_198056.2(SCN5A):c.4437+13C>TSNV Conflicting interpretations of pathogenicity 36762 rs148598985 3:38597919-38597919 3:38556428-38556428
40 SNTA1 NM_003098.2(SNTA1):c.311-6G>CSNV Conflicting interpretations of pathogenicity 36777 rs139532210 20:32026838-32026838 20:33439032-33439032
41 ANK2 NM_001148.6(ANK2):c.11231C>A (p.Thr3744Asn)SNV Conflicting interpretations of pathogenicity 18057 rs121912705 4:114288920-114288920 4:113367764-113367764
42 ANK2 NM_001148.6(ANK2):c.11716C>T (p.Arg3906Trp)SNV Conflicting interpretations of pathogenicity 18059 rs121912706 4:114294462-114294462 4:113373306-113373306
43 CACNB2 NM_201590.2(CACNB2):c.1044+4_1044+7dupAGTAduplication Conflicting interpretations of pathogenicity 191435 rs1456201116 10:18823156-18823157 10:18534227-18534228
44 AKAP9 NM_005751.4(AKAP9):c.4837A>G (p.Met1613Val)SNV Conflicting interpretations of pathogenicity 35670 rs193922723 7:91670132-91670132 7:92040818-92040818
45 ANK2 NM_001148.6(ANK2):c.8166G>A (p.Met2722Ile)SNV Conflicting interpretations of pathogenicity 35691 rs193922637 4:114277940-114277940 4:113356784-113356784
46 CACNA1C NM_000719.7(CACNA1C):c.6031G>A (p.Val2011Ile)SNV Conflicting interpretations of pathogenicity 35770 rs193922615 12:2797859-2797859 12:2688693-2688693
47 CACNA1C NM_000719.7(CACNA1C):c.6307G>T (p.Ala2103Ser)SNV Conflicting interpretations of pathogenicity 35771 rs193922616 12:2800255-2800255 12:2691089-2691089
48 JUP NM_002230.4(JUP):c.909+6C>TSNV Conflicting interpretations of pathogenicity 36426 rs193922705 17:39923625-39923625 17:41767373-41767373
49 KCNH2 NM_172057.2(KCNH2):c.2120G>T (p.Arg707Leu)SNV Conflicting interpretations of pathogenicity 36429 rs36210421 7:150644428-150644428 7:150947340-150947340
50 KCNE2 NM_172201.1(KCNE2):c.170T>C (p.Ile57Thr)SNV Conflicting interpretations of pathogenicity 6054 rs74315448 21:35742947-35742947 21:34370648-34370648

Expression for Cardiac Arrhythmia

Search GEO for disease gene expression data for Cardiac Arrhythmia.

Pathways for Cardiac Arrhythmia

Pathways related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.73 KCNQ1 KCNJ2 KCNH2 GNB5 AKAP9
2
Show member pathways
12.58 SCN5A RYR2 RANGRF KCNQ1 KCNJ2 KCNH2
3
Show member pathways
12.52 RYR2 KCNQ1 KCNJ2 GNB5 CACNA1C
4
Show member pathways
12.27 SCN5A RYR2 KCNQ1 KCNE1 CACNA1C
5 12.21 KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1 GNB5
6 11.94 SCN5A RYR2 KCNQ1 KCNH2
7
Show member pathways
11.89 RYR2 PKP2 JUP CACNA1C
8
Show member pathways
11.84 KCNQ1 KCNJ2 KCNH2
9
Show member pathways
11.37 SCN5A RANGRF KCNQ1 KCNE2 KCNE1 CACNA1C
10 11.07 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
11 10.78 KCNQ1 KCNJ2 KCNE1

GO Terms for Cardiac Arrhythmia

Cellular components related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.18 SCN5A RYR2 RANGRF PKP2 KCNQ1 KCNJ2
2 lysosome GO:0005764 9.71 KCNQ1 KCNE2 KCNE1 ANK2
3 Z disc GO:0030018 9.63 SCN5A RYR2 KCNE1 JUP CACNA1C ANK2
4 sarcolemma GO:0042383 9.62 SCN5A RYR2 CACNA1C ANK2
5 T-tubule GO:0030315 9.56 SCN5A KCNJ2 CACNA1C ANK2
6 desmosome GO:0030057 9.43 PKP2 JUP
7 voltage-gated potassium channel complex GO:0008076 9.43 KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1 AKAP9
8 intercalated disc GO:0014704 9.1 SCN5A RANGRF PKP2 KCNJ2 JUP ANK2

Biological processes related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 10.15 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
2 transmembrane transport GO:0055085 10.1 SCN5A RYR2 KCNQ1 KCNH2 CACNA1C
3 potassium ion transport GO:0006813 9.99 KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1
4 potassium ion transmembrane transport GO:0071805 9.98 KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1
5 regulation of ion transmembrane transport GO:0034765 9.98 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1
6 protein localization to plasma membrane GO:0072659 9.89 PKP2 JUP ANK2
7 cardiac muscle contraction GO:0060048 9.87 SCN5A RYR2 KCNQ1 KCNH2
8 cellular response to drug GO:0035690 9.86 KCNQ1 KCNH2 KCNE2
9 regulation of heart rate GO:0002027 9.86 SCN5A RYR2 RANGRF ANK2
10 cellular response to cAMP GO:0071320 9.84 KCNQ1 KCNE1 AKAP9
11 positive regulation of potassium ion transmembrane transport GO:1901381 9.84 KCNQ1 KCNJ2 KCNH2 KCNE1
12 potassium ion export across plasma membrane GO:0097623 9.83 KCNQ1 KCNH2 KCNE2 KCNE1
13 potassium ion import across plasma membrane GO:1990573 9.82 KCNJ2 KCNH2 KCNE2
14 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.81 KCNQ1 KCNH2 KCNE2 KCNE1
15 regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion GO:0010881 9.8 RYR2 CACNA1C ANK2
16 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.8 RYR2 PKP2 JUP CACNA1C
17 regulation of membrane repolarization GO:0060306 9.8 KCNQ1 KCNJ2 KCNH2 KCNE2 AKAP9
18 cardiac muscle cell action potential involved in contraction GO:0086002 9.8 SCN5A PKP2 KCNJ2 KCNE2 KCNE1 CACNA1C
19 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.8 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1 ANK2
20 regulation of potassium ion transmembrane transport GO:1901379 9.79 KCNH2 KCNE2 KCNE1
21 cell communication by electrical coupling involved in cardiac conduction GO:0086064 9.79 RYR2 PKP2 CACNA1C
22 regulation of cardiac muscle cell contraction GO:0086004 9.78 SCN5A KCNJ2 ANK2
23 membrane repolarization GO:0086009 9.78 KCNQ1 KCNH2 KCNE2 KCNE1
24 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.77 SCN5A KCNJ2 CACNA1C
25 membrane repolarization during action potential GO:0086011 9.77 KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1
26 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.76 KCNQ1 KCNJ2 KCNH2 KCNE1
27 ventricular cardiac muscle cell action potential GO:0086005 9.76 SCN5A RYR2 PKP2 KCNQ1 KCNH2 KCNE2
28 atrial cardiac muscle cell action potential GO:0086014 9.75 SCN5A KCNQ1 ANK2
29 positive regulation of heart rate GO:0010460 9.71 RYR2 KCNQ1
30 regulation of cardiac muscle contraction GO:0055117 9.71 RYR2 ANK2
31 membrane depolarization during action potential GO:0086010 9.71 SCN5A KCNH2
32 positive regulation of sodium ion transport GO:0010765 9.7 SCN5A PKP2
33 negative regulation of delayed rectifier potassium channel activity GO:1902260 9.7 KCNE2 KCNE1
34 calcium ion transport into cytosol GO:0060402 9.7 RYR2 CACNA1C
35 cellular response to epinephrine stimulus GO:0071872 9.69 RYR2 KCNQ1
36 regulation of sodium ion transmembrane transport GO:1902305 9.69 SCN5A RANGRF
37 regulation of cardiac muscle cell action potential involved in regulation of contraction GO:0098909 9.69 RANGRF AKAP9
38 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.68 RYR2 ANK2
39 regulation of delayed rectifier potassium channel activity GO:1902259 9.68 KCNE2 KCNE1
40 positive regulation of potassium ion transmembrane transporter activity GO:1901018 9.68 ANK2 AKAP9
41 bundle of His cell-Purkinje myocyte adhesion involved in cell communication GO:0086073 9.67 PKP2 JUP
42 SA node cell action potential GO:0086015 9.67 SCN5A ANK2
43 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.67 SCN5A KCNQ1
44 membrane depolarization during SA node cell action potential GO:0086046 9.66 SCN5A ANK2
45 membrane depolarization during AV node cell action potential GO:0086045 9.65 SCN5A CACNA1C
46 sarcoplasmic reticulum calcium ion transport GO:0070296 9.65 RYR2 ANK2
47 desmosome assembly GO:0002159 9.65 PKP2 JUP
48 membrane depolarization during atrial cardiac muscle cell action potential GO:0098912 9.64 SCN5A CACNA1C
49 regulation of atrial cardiac muscle cell action potential GO:0098910 9.63 RYR2 ANK2
50 regulation of SA node cell action potential GO:0098907 9.63 RYR2 ANK2

Molecular functions related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 calmodulin binding GO:0005516 9.84 SCN5A RYR2 KCNQ1 CACNA1C
2 ion channel activity GO:0005216 9.78 SCN5A RYR2 KCNH2 CACNA1C
3 voltage-gated ion channel activity GO:0005244 9.73 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 CACNA1C
4 potassium channel activity GO:0005267 9.71 KCNQ1 KCNH2 KCNE2 KCNE1
5 scaffold protein binding GO:0097110 9.7 SCN5A KCNQ1 KCNH2
6 potassium channel regulator activity GO:0015459 9.67 KCNE2 KCNE1 AKAP9
7 voltage-gated potassium channel activity GO:0005249 9.67 KCNQ1 KCNH2 KCNE2 KCNE1
8 protein kinase A regulatory subunit binding GO:0034237 9.63 RYR2 KCNQ1 AKAP9
9 delayed rectifier potassium channel activity GO:0005251 9.62 KCNQ1 KCNH2 KCNE2 KCNE1
10 inward rectifier potassium channel activity GO:0005242 9.61 KCNJ2 KCNH2 KCNE2
11 protein kinase A catalytic subunit binding GO:0034236 9.56 RYR2 KCNQ1
12 alpha-catenin binding GO:0045294 9.55 PKP2 JUP
13 cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication GO:0086083 9.51 PKP2 JUP
14 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.46 KCNQ1 KCNH2 KCNE2 KCNE1
15 ion channel binding GO:0044325 9.28 SCN5A RYR2 RANGRF PKP2 KCNQ1 KCNE2
16 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 9.26 KCNQ1 KCNJ2 KCNH2 KCNE1

Sources for Cardiac Arrhythmia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....